Medications not yet evaluated by P&T are considered NON-FORMULARY. Always check 2 unique patient identifiers - NAME and DATE OF BIRTH - at every step!
Please be sure to document all clinical activities daily.
Search results for:

daratumumab-hyaluronidase-fihj

daratumumab-hyaluronidase-fihj
Drug Name Form Strength Formulary Unrestricted Formulary Restricted Non-Formulary Interchange
Darzalex Faspro INJECTION, SUBCUTANEOUS 120 mg and 2000 mg/mL      
Comments:

Restricted to oncology in the outpatient setting. Insurance certification or PAP eligibility review required with each case before use. Darzalex intravenous may be used as an option in some cases. May be administered as "patient own medication" through PAP.

Reviewed: April 2021 (Darzalex Faspro)

Last updated: May. 26, 2021






This site is intended for the staff of Huntsville Hospital.
While others may view accessible pages, Huntsville Hospital makes no warranty, express or implied,
as to the use of this information outside of Huntsville Hospital.
Please note than many documents are accessible via the provided link
only when connected to the Huntsville Hospital intranet.

Copyright © 2026 Rpharmy, LLC ­ All Rights Reserved